Fy. Ntanios et al., Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on sterol absorption in hypercholesterolemic subjects, METABOLISM, 48(1), 1999, pp. 68-73
To investigate the potential effects of high-dose 3-hydroxy-3-methylglutary
l-coenzyme A (HMG-CoA) reductase inhibitor on plasma phytosterol, total cho
lesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density li
poprotein cholesterol (HDL-C), and triglyceride (TG), hypercholesterolemic
subjects received 40 or 80 mg/d simvastatin in a 24-week prospective clinic
al trial. Plasma lipid levels were analyzed enzymatically, and plasma phyto
sterol concentrations were determined using gas-liquid chromatography. The
change in the plasma phytosterol-campesterol level was used as an indicator
of cholesterol absorption in humans. Simvastatin treatment reduced plasma
campesterol (-24%, P=.017) but did not affect circulating stigmasterol and
sitosterol levels. A dose of 80 mg/d simvastatin produced a larger decrease
(P =.050) in plasma campesterol (0.1680 mmol/L) than 40 mg/d (0.0237 mmol/
L) versus baseline. There was a positive correlation between plasma campest
erol and TC both before (r =.54, P =.027) and after (r =.63, P =.009) treat
ment. Plasma To and TG levels did not differ between groups receiving 40 or
80 mg/d simvastatin. Simvastatin treatment reduced circulating TC, LDL-C,
and TG by 40%, 50%, and 33% (P <.007), respectively. There was no significa
nt effect of simvastatin on plasma HDL-C, but the HDL-C/LDL-C ratio increas
ed 1.3-fold (P <.0001). In conclusion, this HMG-CoA reductase inhibitor red
uces the plasma campesterol level, a marker of cholesterol absorption, whic
h may contribute to the mechanism by which simvastatin decreases circulatin
g cholesterol levels. Copyright (C) 1999 by W.B. Saunders Company.